KRRO Korro Bio, Inc.
Financings ·
Korro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028.
Korro Bio cut about 34% of its workforce on November 12, 2025, paused its Novo Nordisk collaboration for 12 months, and said the moves extend its cash into the second half of 2027. Its chief medical officer also resigned, and its lead RNA editing candidate fell short of the protein levels the company had projected.
The RNA editing company ended the third quarter of 2025 with $102.5 million in cash and securities. Its AATD drug candidate KRRO-110 did not reach projected protein levels.
Korro Bio began a restructuring on May 7, 2025, cutting about 20% of its workforce and taking one-time charges of about $1.2 million. The company cut costs before its first interim data readout, and its net loss widened in the first quarter.
Korro Bio's S-3 shelf registers up to $400,000,000 of securities. Its sales agreement with TD Securities (USA) LLC covers up to $100,000,000 of common stock, and the filing gives no cash balance.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $6.4 million | $2.3 million |
| Research and development | $65.6 million | $63.6 million |
| Net income (loss) | -$117.3 million | -$83.6 million |
| Cash from operations | -$78.6 million | -$60.1 million |
| Cash and equivalents | $21.8 million | $55.6 million |
| Short-term investments | $53.3 million | $70.5 million |
Our latest story on this, dated Mar 9, 2026: "Korro Bio agrees to $85 million private placement led by Venrock Healthcare". The story links the filing or release it is based on. Read the story.
Korro Bio, Inc. trades under the ticker KRRO on NASDAQ.
Korro Bio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Korro Bio, Inc. is 1703647. Its filings are on SEC EDGAR.
14,725,646 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Korro Bio, Inc. under United States.
Our directory classifies Korro Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Korro Bio, Inc. is US5009461089.
aibio.space lists Korro Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$6.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Korro Bio, Inc. reported a net loss of $117.3 million for the fiscal year ended Dec 31, 2025, and used $78.6 million of cash in operations, per its annual report to the SEC.
$65.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$115.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Korro Bio, dated Mar 9, 2026: "Korro Bio agrees to $85 million private placement led by Venrock Healthcare". Korro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028. Source.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.02,2.05,5.02,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio